Loading cancer entity…
Loading cancer entity…
Clinical trials
204 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (28)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 |
| clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT02684071 | Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors | terminated | Phase 2 | 3 | Nicklaus Children's Hospital f/k/a Miami Children's HospitalOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT02689336 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT01601184 | Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | terminated | Phase 1 / Phase 2 | 24 | Centre Leon BerardOTHER | 4 | May 21, 2019 | clinicaltrials |
| NCT00031590 | Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma | terminated | Phase 2 | 30 | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01857453 | Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas(RSMA2010) | unknown | Phase 2 | 97 | Central Hospital, Nancy, FranceOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02332889 | Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | terminated | Phase 1 / Phase 2 | 1 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT01708174 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | completed | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 11, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT02681705 | Radiation Therapy and Combination Chemotherapy for Medulloblastoma | unknown | Phase 2 | 60 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00939484 | Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01239316 | Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00070525 | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00404495 | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | completed | Phase 2 | 83 | PfizerINDUSTRY | 8 | Apr 18, 2012 | clinicaltrials |
| NCT00520936 | A Study of Pemetrexed in Children With Recurrent Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00180791 | High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood | unknown | Phase 2 | 71 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 18, 2007 | clinicaltrials |
| NCT00180947 | Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse | unknown | Phase 2 | 210 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 8, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Jul 27, 2021source: clinicaltrials